JNCCN 360 - MM - Ongoing CE Activities

Editors:

Shaji K. Kumar, MD

Prashant Kapoor, MD, FACP

Advertisement

Advertisement

Ongoing CE Activities

Also Consider: Precision Hematology Webinar Series (0 Credits)

BCMA Who and When: Immunotherapies in Patients with RRMM

Biallelic Deletion of 1p32 Defines Ultra-High-Risk Myeloma

Case Challenges in Newly Diagnosed Multiple Myeloma

Clinical Update on B-Cell Maturation Antigen-Directed Therapies for Multiple Myeloma

Current Evidence and Guidelines for Treatment Selection for Relapsed/Refractory Multiple Myeloma

Expanding Access to Novel Treatment Approaches for Multiple Myeloma

Guideline Recommendations for Treatment Selection and Sequencing in Relapsed/Refractory Multiple Myeloma

Harnessing the Potential of Novel Therapies in Multiple Myeloma

Oncology Today with Dr Neil Love: Current Role of Minimal Residual Disease Assessment in the Management of Multiple Myeloma and Chronic Lymphocytic Leukemia

Optimizing Triplet and Quadruplet Therapy Regimens in Multiple Myeloma

Practical Considerations With Using CAR T-cell Therapies in Multiple Myeloma

Rapidly Evolving Paradigms in Multiple Myeloma: Applying Current Data in the Clinic

Relapsed/Refractory Multiple Myeloma: An Expert-Guided Tour Through New and Emerging Therapies

Simulation Challenge in Diagnosing and Treating Hematologic Malignancies

Sections

NCCN Resources

Copyright © 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.